A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCL
What is the purpose of this trial?
The objective of this study is to investigate the safety, tolerability and antitumor activity of novel combination therapies administered in subjects with advanced EGFRm NSCLC.
- Trial withMedImmune, Inc
- Start Date06/13/2018
- End Date11/25/2021
- Last Updated08/30/2019
- Study HIC#2000021942